Inhibition of P450 17 as a new strategy for the treatment of prostate cancer

被引：29

作者：

Leroux, F ^{[1
]}

机构：

[1] Univ Strasbourg, ECPM, CNRS, UMR 7509,Lab Stereochim, F-67087 Strasbourg, France

来源：

CURRENT MEDICINAL CHEMISTRY | 2005年 / 12卷 / 14期

关键词：

androgen; 17 alpha-hydroxylase-C17,20-lyase; P450; 17; CYP; prostate cancer; steroidal inhibitors; non-steroidal inhibitors; abiraterone; liarozole;

D O I：

10.2174/0929867054367185

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The cytochrome P450 monooxygenase enzyme system is involved in the synthesis and/or degradation of a large number of endogenous compounds and in the biotransformation of drugs and other xenobiotics. 17 alpha-Hydroxylase-C17,20-lyase (P450 17, CYP 17) is the key enzyme of the androgen biosynthesis. As androgens have been implicated in the development and progression of prostate cancer, this enzyme has become a promising therapeutic target. This paper will review the possible approaches dealing with P450 17 inhibition as a chemotherapeutic strategy in the struggle against prostate cancer.

引用

页码：1623 / 1629

页数：7

共 54 条

[21] PYRIDYL-SUBSTITUTED TETRAHYDROCYCLOPROPA[A]NAPHTHALENES - HIGHLY-ACTIVE AND SELECTIVE INHIBITORS OF P450 AROM [J].

HARTMANN, RW ;

BAYER, H ;

GRUN, G ;

SERGEJEW, T ;

BARTZ, U ;

MITRENGA, M .

JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (12) :2103-2111

[22] Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17, and P450 TxA2 [J].

Hartmann, RW ;

Frotscher, M ;

Ledergerber, D ;

Wachter, GA ;

Grun, GL ;

Sergejew, TF .

ARCHIV DER PHARMAZIE, 1996, 329 (05) :251-261

[23]

HARTMANN RW, 1999, Patent No. 9918075

[24]

HIGASHI Y, 1987, ENDOCRINOL JAPON, V34, P105

[25] Synthesis of hydroxy derivatives of highly potent non-steroidal CYP 17 inhibitors as potential metabolites and evaluation of their activity by a non cellular assay using recombinant human enzyme [J].

Hutschenreuter, TU ;

Ehmer, PB ;

Hartmann, RW .

JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2004, 19 (01) :17-32

[26]

Ideyama Y, 1998, PROSTATE, V37, P10

[27] YM116, 2-(1H-imidazol-4-ylmethyl)-9H-carbazole, decreases adrenal androgen synthesis by inhibiting C17-20 lyase activity in NCI-H295 human adrenocortical carcinoma [J].

Ideyama, Y ;

Kudoh, M ;

Tanimoto, K ;

Susaki, Y ;

Nanya, T ;

Nakahara, T ;

Ishikawa, H ;

Fujikura, T ;

Akaza, H ;

Shikama, H .

JAPANESE JOURNAL OF PHARMACOLOGY, 1999, 79 (02) :213-220

[28] Inhibitors of enzymes of androgen biosynthesis:: cytochrome P45017α and 5α-steroid reductase [J].

Jarman, M ;

Smith, HJ ;

Nicholls, PJ ;

Simons, C .

NATURAL PRODUCT REPORTS, 1998, 15 (05) :495-512

[29] The 16,17-double bond is needed for irreversible inhibition of human cytochrome P45017α by abiraterone (17-(3-pyridyl)androsta-5,16-dien-3β-ol) and related steroidal inhibitors [J].

Jarman, M ;

Barrie, SE ;

Llera, JM .

JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (27) :5375-5381

[30] Hormone therapy for prostate cancer: A topical perspective [J].

Klein, EA .

UROLOGY, 1996, 47 (1A) :3-12

← 1 2 3 4 5 6 →